BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Bridge Biotherapeutics Completes Patient Enrollment for Phase 2 Study of BBT-877 in IPF Treatment

Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, an...

July 30, 2024 | News

Menarini Group Announces Positive Phase 3 Trial Results for Obicetrapib in Lowering LDL-C

-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically ...

July 30, 2024 | News

Daewoong Pharmaceutical's Bersiporocin Shows Positive Safety Data in Phase 2 Trial for IPF

Daewoong Pharmaceutical (Co-CEOs Chang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN...

July 30, 2024 | News

Eluminex Biosciences Administers First Dose of EB-105 to Diabetic Macular Edema Patient in US

Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient in...

July 29, 2024 | News

ObvioHealth Secures Strategic Investment from Guardant Health to Boost Oncology Clinical Trials

ObvioHealth, a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company ...

July 26, 2024 | News

Sirnaomics Completes IND-Enabling Studies for siRNA Therapeutic STP125G Targeting ApoC3

Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”),...

July 24, 2024 | News

Pfizer Opens SGD$1 Billion Green Mark Gold-Certified API Manufacturing Facility in Singapore

Invests SGD$1 billion to produce small molecule APIs for oncology, pain, and antibiotic medicines The facility is Green Mark ‘Go...

July 23, 2024 | News

Everest Medicines Doses First Chinese Patient in Global Phase 2b Trial of Zetomipzomib for Lupus Nephritis

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

July 22, 2024 | News

Dermaliq Therapeutics Announces Promising Phase 1b/2a Trial Results for DLQ01 in Treating Male Pattern Baldness

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage dermatology and medical aesthetics company, announced statistically significan...

July 18, 2024 | News

GCCL Launches R&D Division to Bolster Biosimilar and Clinical Trial Analysis Services

Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockb...

July 17, 2024 | News

CordenPharma Announces €900 Million Investment to Expand Peptide Manufacturing Capabilities in US and Europe

CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its Peptide technol...

July 17, 2024 | News

Sanyou Bio and Huadong Medicine Advance SYHD001 ADC Drug to Phase I Clinical Trials

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") has recently announced a significant milestone in collaboration wi...

July 17, 2024 | News

Biosyngen's Groundbreaking CAR-T Therapy BRG01 Approved for Phase II Clinical Trial in China

Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation ...

July 17, 2024 | News

Mabwell's Novel Nectin-4 ADC Approved for Phase II Clinical Trial in Treating Triple-Negative Breast Cancer

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821)...

July 16, 2024 | News

Stay Connected